IPHA
Innate Pharma·NASDAQ
--
--(--)
--
--(--)
1.70 / 10
Underperform
Financial analysis yields a subpar rating (1.7/10). Key weaknesses include low current assets turnover (0.0645) and net profit to total profit ratio (0), while fixed assets turnover (0.9635) and inventory turnover (37.9867) offer limited relief. Gross profit margin is a strong 100%, but it is outweighed by other deficits, leading to an overall constrained fundamental outlook.
Analysis Checks(3/5)
Inventory turnover ratio
Value37.99
Score2/3
Weight163.36%
1M Return-2.63%
Value37.99
Score2/3
Weight163.36%
1M Return-2.63%
Current assets turnover ratio
Value0.06
Score1/3
Weight32.46%
1M Return-0.48%
Value0.06
Score1/3
Weight32.46%
1M Return-0.48%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Gross profit margin (%)
Value100.00
Score2/3
Weight-106.48%
1M Return1.47%
Value100.00
Score2/3
Weight-106.48%
1M Return1.47%
Fixed assets turnover ratio
Value0.96
Score2/3
Weight-8.39%
1M Return0.12%
Value0.96
Score2/3
Weight-8.39%
1M Return0.12%
Inventory turnover ratio
Value37.99
Score2/3
Weight163.36%
1M Return-2.63%
Value37.99
Score2/3
Weight163.36%
1M Return-2.63%
Gross profit margin (%)
Value100.00
Score2/3
Weight-106.48%
1M Return1.47%
Value100.00
Score2/3
Weight-106.48%
1M Return1.47%
Current assets turnover ratio
Value0.06
Score1/3
Weight32.46%
1M Return-0.48%
Value0.06
Score1/3
Weight32.46%
1M Return-0.48%
Fixed assets turnover ratio
Value0.96
Score2/3
Weight-8.39%
1M Return0.12%
Value0.96
Score2/3
Weight-8.39%
1M Return0.12%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Is IPHA fundamentally strong?
- IPHA scores 1.70/10 on fundamentals and holds a Premium valuation at present. Backed by its -305.39% ROE, -373.78% net margin, -3.22 P/E ratio, 26.47 P/B ratio, and -30.92% earnings growth, these metrics solidify its Underperform investment rating.
